Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment
10.3760/cma.j.cn371439-20201208-00109
- VernacularTitle:PD-L1在甲状腺癌中的作用机制及其在诊疗中的应用
- Author:
Yuping WU
1
;
Xiaoyu ZHANG
;
Keyi LU
Author Information
1. 山西医科大学第一医院核医学科 分子影像精准诊疗省部共建协同创新中心，太原 030001
- Keywords:
Thyroid neoplasms;
Suppressor factors, immunologic;
Prognosis;
Programmed death-ligand 1
- From:
Journal of International Oncology
2021;48(9):560-563
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) participate in the regulation of immune checkpoint and are closely related to the occurrence and development of thyroid carcinoma. PD-L1 is expressed differently in different types of thyroid cancer and can be used as a biomarker for the diagnosis of some tumors. The expression of PD-L1 in thyroid cancersis associated with higher tumor invasiveness and higher risk of recurrence. PD-1/PD-L1 immune checkpoint is a promising target for the treatment of some thyroid cancers. Further discussion of the mechanism of PD-1/PD-L1 pathway and its role in the diagnosis and treatment of thyroid cancer and the biomarkers related to the therapeutic effect can provide new ideas for the diagnosis and treatment of thyroid cancer.
